Ann: Suspension from Official Quotation, page-119

I have asked for the above post to be deleted because my thought Nomura was “keen on lithium” came from a link I cannot find now .

In looking for that link I found that on February 12, 2020 Nomura upgraded its rating on Ganfeng to a buy - partly based on lower spodumene concentrate costs vs strong hydroxide orders.
http://www.etnet.com.hk/www/eng/sto...;newsid=ETE300212147&page=1&code=1772

Coincidentally this was the same day Altura announced the three year extension [see here] of the loan notes.

Also whilst the return on Nomura shareholders equity in the three months to June 30 was 21%, it seems it is not doing so well after all.

Bloomberg Quint wrote in May a new CEO was appointed to Nomura thought to be partly charged with reducing Nomura’s 23 billion yen worth of loans
https://www.bloombergquint.com/business/nomura-s-new-ceo-set-to-unveil-strategy-to-stabilize-profit
.. “Kentaro Okuda may redouble his predecessor’s efforts to reduce the firm’s reliance on trading and shift it toward more stable earnings drivers such as advice to companies and wealthy Japanese individuals.
The impetus for doing so was made clear during last quarter’s market turmoil, when writedowns on loans and investments led to Nomura’s first loss in five quarters...”